Loading cancer entity…
Loading cancer entity…
Clinical trials
20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | recruiting | Phase 3 | 478 | National Cancer Institute (NCI)NIH | 5 | Sep 24, 2026 | clinicaltrials |
| NCT02176967 | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma | active not recruiting | Phase 3 | 621 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 |
| clinicaltrials |
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | recruiting | Phase 3 | 750 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT07375563 | Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma(NB-NK-2026) | recruiting | Phase 3 | 5 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06071897 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | recruiting | Phase 3 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials